Tag: KDC-MN-1415

  • Teduglutide

    Dipeptidyl peptidase-IV-resistant glucagon-like peptide-2 analog and GLP-2 receptor agonist

    A recombinant 33-amino-acid analog of human glucagon-like peptide-2 bearing a single glycine-for-alanine substitution at position 2 that confers resistance to dipeptidyl peptidase-IV degradation, developed by NPS Pharmaceuticals and approved for the treatment of short bowel syndrome with intestinal failure in adults and pediatric patients dependent on parenteral support.

    Abstract

    Teduglutide is a recombinant analog of human glucagon-like peptide-2 (GLP-2) and the first GLP-2 receptor agonist approved for clinical use in the treatment of short bowel syndrome associated with intestinal failure (SBS-IF). The compound differs from native human GLP-2 by a single amino acid substitution: glycine replaces alanine at position 2 from the N-terminus, eliminating the dipeptidyl peptidase-IV (DPP-IV) cleavage site and extending the plasma elimination half-life from approximately 7 minutes (native GLP-2) to approximately 2 to 3 hours after subcutaneous administration [1, 2].

    The intestinotrophic actions of teduglutide are mediated through GLP-2R activation on subepithelial myofibroblasts, which triggers downstream release of insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), and keratinocyte growth factor (KGF) [3, 4]. These paracrine mediators drive crypt cell proliferation, inhibit enterocyte apoptosis, increase villus height, enhance mucosal barrier function, slow gastric emptying, reduce gastric acid secretion, and increase mesenteric blood flow [5]. The composite physiological effect is an expansion of absorptive intestinal surface area and an improvement in the efficiency of fluid and nutrient absorption in patients with shortened bowel.

    Clinical development centered on the pivotal Phase 3 STEPS trial (Study of Teduglutide Effectiveness in Parenteral Nutrition-Dependent Short-Bowel Syndrome Subjects), in which 86 adult SBS-IF patients were randomized to teduglutide 0.05 mg/kg/day or placebo for 24 weeks [6]. The primary endpoint (20 to 100 percent reduction in parenteral support volume at weeks 20 and 24) was met by 63 percent of teduglutide-treated patients compared to 30 percent of placebo-treated patients (P = 0.002). Three teduglutide-treated patients achieved complete enteral autonomy (full independence from parenteral support). Long-term extension studies (STEPS-2, STEPS-3) demonstrated sustained reductions in parenteral support requirements over 30 months or more, with additional patients achieving enteral autonomy on continued treatment [7, 8].

    Teduglutide received European Commission marketing authorization as Revestive in August 2012, United States Food and Drug Administration (FDA) approval as Gattex in December 2012 for adult SBS-IF patients dependent on parenteral support, and FDA pediatric indication expansion in May 2019 for patients one year of age and older [9, 10]. The compound was developed by NPS Pharmaceuticals (subsequently acquired by Shire, then Takeda), with Takeda holding global commercial rights.

    The principal safety concerns are the trophic effects of sustained GLP-2R stimulation on intestinal epithelium. Colorectal polyps have been reported in clinical trials and postmarketing surveillance at rates higher than placebo, necessitating colonoscopy within 6 months before treatment initiation, after 1 year of treatment, and every 5 years thereafter [11]. Intestinal obstruction, biliary and pancreatic disease, and fluid overload from increased intestinal absorption are additional monitored risks.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.